99% Abiraterone Pharmaceutical Raw Material Abiraterone Acetate





Product Name : Abiraterone
Alias : 17-(3-Pyridyl)androsta-5,16-dien-3beta-ol
CAS register number: 154229-19-3
Molecular Formula: C24H31NO
Molecular Weight: 349.51
Assay: 98%
Appearance: White powder
Grade: Pharmaceutical Grade
Storage: Shading, confined preservation
 

Description

Abiraterone is a drug used in combination with in metastatic castration-resistant prostate cancer (formerly horm**-resistant or horm**-refractory prostate cancer) -- i.e., prostate cancer not responding to androgen deprivation or treatment with antiandrogens. It is formulated as the prodrug abiraterone acetate and marketed under the trade name Zytiga. Cadila Pharmaceuticals has recently started marketing Abiraterone acetate under the trade name Abretone.
After an expedited six-month review, abiraterone was approved by the U.S. Food and Drug Administration (FDA) in April 2011. In Phase III trials, it extended median survival to 14.8 months versus 10.9 months placebo, and the trial was stopped because of the successful outcome.


Applications

It is indicated for use in combination with as a treatment for metastatic castration-resistant prostate cancer. It has received FDA (28 April 2011), EMA (23 September 2011), MHRA (5 September 2011) and TGA (1 March 2012) approval for this indication.[3][4][5][6] In Australia it is covered by the Pharmaceutical Benefits Scheme when being used to treat castration-resistant prostate cancer and given in combination with (subject to the conditions that the patient is not currently receiving chemotherapy, is either resistant or intolerant of docetaxel, has a WHO performance status of <2, and his disease has not since become progressive since treatment with PBS-subsidised abiraterone has commenced).



Medical Usage for Active Pharmaceutical Ingredients Abiraterone
 
(1) Abiraterone, a ster oidal cytochrome P 450 17alpha-hydroxylase-17,20-lyase inhibitor (CYP17), is currently undergoing phase II clinical trials as a potential drug for the treatment of androgen-dependent pr ostate cancer.
 
(2) Currently, for patients of advanced prostate cancer, androgen deprivation therapy including drugs and surgery is generally the preferred method of including drugs and surgery in order to reduce the testicular androgen synthesis. However, this treatment can't suppress other parts of the body for yielding the male horm**.
(3) Abiraterone is a therapeutic agent for prostate cancer with the English name for Abiraterone. It is developed by researchers coming from the British Royal Marsden Hospital located in southwest (world-renowned cancer research treatment center). It is kind of drug which is able to repress any part of the body for androgen production. It can not only reduce the levels of the prostate-specific antigen (PSA) which represents the tu mor activity, but also helps to shrink the tu mor. It can also apply to cancer patients who have been subject to chemotherapy in the past, revealing treatment hope.


How to use abiraterone acetate

Use abiraterone acetate as directed by your doctor. Check the label on the medicine for exact dosing instructions.
* An extra patient leaflet is available with abiraterone acetate. Talk to your pharmacist if you have questions about this information.
* Take abiraterone acetate by mouth on an empty stomach at least 1 hour before or 2 hours after eating. Do NOT take it with food. The amount of abiraterone acetate in your body may be increased if you take it with food. This may increase the risk of side effects.
* Swallow abiraterone acetate whole with water. Do not break, crush, or chew before swallowing.
* If you miss a dose of abiraterone acetate, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once. If you miss more than 1 dose, contact your doctor.
Ask your health care provider any questions you may have about how to use abiraterone acetate.

 

Storage

- It is recommended to store at the room temperature below 30 degrees C.
- Keep the drug away from direct sunlight, heat and moisture.
- Do not let the drug at the sight and reach of children.


Order Process

99% Abiraterone Pharmaceutical Raw Material Abiraterone Acetate





Product Name : Abiraterone
Alias : 17-(3-Pyridyl)androsta-5,16-dien-3beta-ol
CAS register number: 154229-19-3
Molecular Formula: C24H31NO
Molecular Weight: 349.51
Assay: 98%
Appearance: White powder
Grade: Pharmaceutical Grade
Storage: Shading, confined preservation
 

Description

Abiraterone is a drug used in combination with in metastatic castration-resistant prostate cancer (formerly horm**-resistant or horm**-refractory prostate cancer) -- i.e., prostate cancer not responding to androgen deprivation or treatment with antiandrogens. It is formulated as the prodrug abiraterone acetate and marketed under the trade name Zytiga. Cadila Pharmaceuticals has recently started marketing Abiraterone acetate under the trade name Abretone.
After an expedited six-month review, abiraterone was approved by the U.S. Food and Drug Administration (FDA) in April 2011. In Phase III trials, it extended median survival to 14.8 months versus 10.9 months placebo, and the trial was stopped because of the successful outcome.


Applications

It is indicated for use in combination with as a treatment for metastatic castration-resistant prostate cancer. It has received FDA (28 April 2011), EMA (23 September 2011), MHRA (5 September 2011) and TGA (1 March 2012) approval for this indication.[3][4][5][6] In Australia it is covered by the Pharmaceutical Benefits Scheme when being used to treat castration-resistant prostate cancer and given in combination with (subject to the conditions that the patient is not currently receiving chemotherapy, is either resistant or intolerant of docetaxel, has a WHO performance status of <2, and his disease has not since become progressive since treatment with PBS-subsidised abiraterone has commenced).



Medical Usage for Active Pharmaceutical Ingredients Abiraterone
 
(1) Abiraterone, a ster oidal cytochrome P 450 17alpha-hydroxylase-17,20-lyase inhibitor (CYP17), is currently undergoing phase II clinical trials as a potential drug for the treatment of androgen-dependent pr ostate cancer.
 
(2) Currently, for patients of advanced prostate cancer, androgen deprivation therapy including drugs and surgery is generally the preferred method of including drugs and surgery in order to reduce the testicular androgen synthesis. However, this treatment can't suppress other parts of the body for yielding the male horm**.
(3) Abiraterone is a therapeutic agent for prostate cancer with the English name for Abiraterone. It is developed by researchers coming from the British Royal Marsden Hospital located in southwest (world-renowned cancer research treatment center). It is kind of drug which is able to repress any part of the body for androgen production. It can not only reduce the levels of the prostate-specific antigen (PSA) which represents the tu mor activity, but also helps to shrink the tu mor. It can also apply to cancer patients who have been subject to chemotherapy in the past, revealing treatment hope.


How to use abiraterone acetate

Use abiraterone acetate as directed by your doctor. Check the label on the medicine for exact dosing instructions.
* An extra patient leaflet is available with abiraterone acetate. Talk to your pharmacist if you have questions about this information.
* Take abiraterone acetate by mouth on an empty stomach at least 1 hour before or 2 hours after eating. Do NOT take it with food. The amount of abiraterone acetate in your body may be increased if you take it with food. This may increase the risk of side effects.
* Swallow abiraterone acetate whole with water. Do not break, crush, or chew before swallowing.
* If you miss a dose of abiraterone acetate, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once. If you miss more than 1 dose, contact your doctor.
Ask your health care provider any questions you may have about how to use abiraterone acetate.

 

Storage

- It is recommended to store at the room temperature below 30 degrees C.
- Keep the drug away from direct sunlight, heat and moisture.
- Do not let the drug at the sight and reach of children.


Order Process